- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06716463
급성 저산소증 호흡 부전 또는 발관 후 실패가 있는 비삽관 환자에서 비침습적 모니터링을 사용한 비침습적 인공호흡기 지원 실패 예측. PREVISION 연구 (PREVISION)
급성 저산소증 호흡 부전 또는 발관 후 실패가 있는 비삽관 환자에서 비침습적 모니터링을 사용한 비침습적 인공호흡기 지원 실패 예측: PREVISION 연구
The goal of this observational study is to assess the potential non-invasive tools (e.g. regional ventilation, respiratory muscle response, lung mechanic's parameters) to identify the risk of failure when using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV).
The main question, it aims to answer is:
Does abnormal regional ventilation could predict HFNC or NIV failure?
연구 개요
상태
정황
상세 설명
This is a single-center, prospective, physiological study.
The study will enroll patient who has used either HFNC or NIV for the indications of 1. to prevent worsening acute hypoxemic respiratory failure or 2. to prevent reintubation. Once being confirmed to meet the inclusion criteria, the research team will apply the electrical impedance tomography (EIT) on the patient and start recording for 5-10 minutes as well as perform diaphragm and parasternal intercostal muscle ultrasound when the patient is using HFNC or NIV. The current HFNC or NIV setting, some lung mechanic's parameters (e.g. rapid shallow breathing trial (RSBI), negative airway pressure generated during the first 100 milisecond (P0.1), end-expiratory occlusion pressure(ΔPocc) derived from NIV machine), patient's characteristic, dyspnea scores (intensive care respiratory distress observation scale, IC-RDOS; work of breathing scale; self-report of dyspnea visual analog scale, D-VAS), ICU and hospital length of stay will be also collected.
The investigator will use EIT to visualize where air goes in the patient's lung and inspiratory muscle ultrasonography (diaphragm and parasternal intercostal muscle) to visualize the muscle activities when using HFNC or NIV. EIT is a measurement often used in the ICU since it allows easy visualization and is a non-invasive technique. The sensors measure electrical current changes during inspiration and expiration and will not cause any pain or radiation concerns. The EIT belt (3-cm diameter) will be placed around the chest without causing adverse event/discomfort/pain.
The duration of study will be approximately 30 minutes. The study will be conducted one time for one enrolled patient.
HFNC or NIV (device) failure is considered as either intubation/reintubation or death, whatever has come first. It will be followed up to 7 days.
The investigators will proceed with the measurements only with agreement from the clinical team. The investigators will analyze the data collected offline with a dedicated software afterwards.
After these study procedures are completed, data will also be collected from the participant's chart and combined with relevant information from the HFNC or NIV settings and vital functions. Confidentiality will be maintained throughout the entire study.
연구 유형
등록 (추정된)
연락처 및 위치
연구 장소
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5B 1W8
- St. Michael's Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
Patient who is using high flow nasal cannula (HFNC) or non-invasive ventilation (NIV) to either prevent 1. intubation in the context of acute hypoxemic respiratory failure or 2. reintubation in the context of high risk group of extubation.
설명
Inclusion Criteria:
- Age of ≥ 18 years
- Using NIV or HFNC anywhere in the hospital
Exclusion Criteria:
- Chronic CO2 retention
- Neuromuscular disorder
- Requiring home NIV (CPAP or BIPAP)
- Tracheostomy
- Contraindication to EIT placement: pacemaker/defibrillator implantation, burns at the area of EIT placement
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 관찰 모델: COHORT
- 시간 관점: PROSPECTIVE
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Difference in regional ventilation distribution (%)
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
The primary endpoint is to assess regional ventilation distribution (%) when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Diaphragm or parasternal intercostal muscle thickening fraction
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess ultrasound measurement of inspiratory muscle activity when using HFNC or NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Rapid shallow breathing index (RSBI) in mL/breaths/min
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess non-invasive respiratory - rapid shallow breathing index (RSBI) derived from NIV to predict a device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory drive using negative airway pressure generated during the first 100 millisecond (P0.1)
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory drive - using negative airway pressure generated during the first 100 millisecond (P0.1) in cmH2O to predict device failure. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Respiratory effort using end-expiratory airway occlusion pressure (ΔPocc)
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess respiratory effort using end-expiratory airway occlusion pressure (ΔPocc) in cmH2O to predict device failure |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The intensive care respiratory distress observation scale (IC-RDOS)
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the level of dyspnea using intensive care respiratory distress observation scale (IC-RDOS) to predict a device failure. There is no minimum or maximum range depending on patient's heart rate, the higher score means worse outcome. When the score ≥ 2.4, it likely indicates clinically important dyspnea requiring clinical management. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
The work of breathing scale
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess the work of breathing scale to predict a device failure. Minimum is 3 and maximum is 12, the higher score means worse outcome. When the score > 4, it likely indicates severe respiratory distress. |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
|
Self-report of dyspnea visual analog scale (D-VAS)
기간: The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
To assess self-report of dyspnea visual analog scale (D-VAS) to predict a device failure. Minimum is 0 and maximum is 10, the higher score means worse outcome. When the score > 3, it likely indicates dyspnea and being used for quality of palliative care unit |
The parameter is measured at the time of enrolment. Failure of HFNC or NIV is adjudicated at 7 days.
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- Unity Health Toronto
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .